--- title: "A Look At Hansoh Pharmaceutical Group’s Valuation As XINYUE Gains Third Rare Disease Approval In China" type: "News" locale: "en" url: "https://longbridge.com/en/news/282920469.md" description: "Hansoh Pharmaceutical Group has received NMPA approval for XINYUE's third indication, expanding its rare disease portfolio. The stock is currently priced at HK$39.4, reflecting a 21.6% return over 30 days and an 82.34% return over the past year. Despite strong earnings growth of 27.1%, the company's P/E ratio of 37.4x is significantly higher than industry averages, indicating potential overvaluation. However, a DCF analysis suggests shares may be undervalued at HK$39.4 compared to an estimated future cash flow value of HK$51.04. Investors should consider the mixed signals regarding valuation and growth expectations." datetime: "2026-04-16T01:40:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282920469.md) - [en](https://longbridge.com/en/news/282920469.md) - [zh-HK](https://longbridge.com/zh-HK/news/282920469.md) --- # A Look At Hansoh Pharmaceutical Group’s Valuation As XINYUE Gains Third Rare Disease Approval In China Hansoh Pharmaceutical Group (SEHK:3692) has secured NMPA approval for XINYUE’s third indication, targeting adult patients with generalized myasthenia gravis, and expanding its rare autoimmune disease footprint supported by positive Phase III MINT trial data. See our latest analysis for Hansoh Pharmaceutical Group. The XINYUE approval lands at a time when the share price has climbed to HK$39.4, with a 30 day share price return of 21.6% and a 1 year total shareholder return of 82.34%. This suggests recent momentum on top of already strong longer term gains. If this kind of rare disease news has your attention, it can be worth widening your watchlist with other healthcare names using our screener of 125 healthcare AI stocks With Hansoh Pharmaceutical Group now trading at HK$39.4 and still showing both an intrinsic and analyst target discount, investors may be wondering whether there is more upside left or if the market is already pricing in future growth. ## Preferred P/E of 37.4x, Is it justified? On a P/E of 37.4x at HK$39.4, Hansoh Pharmaceutical Group sits well above both its own fair value estimate and the peer group, which points to a rich valuation. The P/E multiple compares the share price to earnings per share and is a quick way to see how much you are paying for each unit of profit. For a pharmaceutical company with meaningful earnings, a higher P/E often reflects investor expectations for future growth, product approvals or sustained profitability. In Hansoh Pharmaceutical Group's case, several factors point to the market paying up. Earnings grew 27.1% over the past year, ahead of its 5 year average of 17.4% and ahead of the Hong Kong Pharmaceuticals industry, which saw a 1.2% decline. Profit margins are currently 37%, above last year's 35.7%, and earnings growth over the past five years has averaged 17.4% per year. The SWS DCF model also indicates the shares trade about 22.8% below an estimated future cash flow value of HK$51.04, suggesting cash flow based valuation is more supportive than the current P/E might imply. However, the estimated fair P/E of 29x sits well below the current 37.4x. This highlights how far sentiment has moved above what the regression based fair ratio suggests could be a more grounded level if expectations cool. Compared with peers, the premium is even starker. Hansoh Pharmaceutical Group's 37.4x P/E is higher than the Hong Kong Pharmaceuticals industry average of 15.2x and above the peer average of 24.3x. That gap indicates the market is assigning the company a premium multiple that is more than double the sector level and clearly above what the SWS fair ratio model indicates. Explore the SWS fair ratio for Hansoh Pharmaceutical Group **Result: Price-to-Earnings of 37.4x (OVERVALUED)** However, recent 90 day share price weakness and the premium 37.4x P/E leave the story vulnerable if drug approvals, licensing partnerships, or earnings execution disappoint. Find out about the key risks to this Hansoh Pharmaceutical Group narrative. ## Another View: DCF Says the Shares Look Cheap While the 37.4x P/E suggests Hansoh Pharmaceutical Group is priced for high expectations, the SWS DCF model points the other way. With the shares at HK$39.4 versus an estimated future cash flow value of HK$51.04, the model indicates roughly a 22.8% undervaluation. Which signal deserves more weight? Look into how the SWS DCF model arrives at its fair value. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hansoh Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 233 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. ## Next Steps With the signals pointing in different directions, what matters most is how you read the data and how quickly you act on it. To weigh the upside that others are already watching, take a closer look at the company's 3 key rewards. ## Looking for more investment ideas? If you are weighing Hansoh Pharmaceutical Group, it is worth lining it up against a few other ideas so you can see where the best balance of quality, value, and resilience might sit. - Target quality at a discount by scanning companies that combine strong fundamentals with attractive pricing using the 233 high quality undervalued stocks. - Prioritise staying power by focusing on businesses with robust finances through the solid balance sheet and fundamentals stocks screener (391 results). - Hunt for potential up and comers that are not yet widely followed by checking the screener containing 574 high quality undiscovered gems. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Related Stocks - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) ## Related News & Research - [Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug](https://longbridge.com/en/news/286266501.md) - [Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC](https://longbridge.com/en/news/285857826.md) - [AIA Singapore targets 90% of illness claims](https://longbridge.com/en/news/287132135.md) - [13:07 ETEveryLife Foundation Scientific Workshop Advances Patient-Centered Approaches to Rare Disease Therapy Development](https://longbridge.com/en/news/286447881.md) - [09:03 ETOrthoArizona Expands Pinnacle Pain with New Chandler Facility and New Physician](https://longbridge.com/en/news/287070954.md)